Pathology scoring plays a central role in biomedical research, drug development, biomarker evaluation, and disease characterization. Whether researchers are grading tumor morphology, quantifying immunohistochemical staining, assessing fibrosis, measuring inflammation, or evaluating treatment-inducedRead More…
Whole-slide imaging (WSI) has changed how pathology data can be captured, stored, reviewed, and analyzed. In preclinical research, this shift is especially important because tissue slides are often used to evaluate diseaseRead More…
Introduction: Why “Faster” Can Be More Valuable Than “First-in-Class” In drug discovery, novelty has long been treated as a strategic advantage. A new mechanism of action (MOA), a first-in-class target, or anRead More…
Target identification is one of the most important starting points in modern drug discovery. A promising therapeutic idea often begins with a biological question: which gene, protein, pathway, cell type, or molecularRead More…
The landscape of cancer immunotherapy has been irrevocably altered by the advent of mRNA technology. Following the unprecedented success of prophylactic mRNA vaccines on a global scale, the scientific community has rapidlyRead More…
The landscape of oncology has been fundamentally reshaped by the advent of adoptive cell therapies, particularly T cell receptor-engineered T cell (TCR-T) therapy. Unlike Chimeric Antigen Receptor (CAR) T cells, which areRead More…
The landscape of targeted therapeutics and diagnostics is experiencing a profound paradigm shift. For decades, monoclonal antibodies have dominated the field of targeted biologicals. However, the rise of oligonucleotides has brought aRead More…
In the rapidly evolving landscape of therapeutic protein development, the integration of Artificial Intelligence (AI) has shifted the paradigm from “discovery via screening” to “discovery via design.” However, even the most sophisticatedRead More…
In the landscape of modern drug discovery, the era of simply finding a molecule that “binds” to a target is over. The contemporary challenge lies in functional precision—dictating exactly how a therapeuticRead More…
De novo drug design has moved from a niche computational exercise to a central pillar of AI-driven drug discovery. With rising R&D costs, multi-year timelines, and high attrition rates, the ability toRead More…